FACTOR CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-05-21 pm EDT | ||
| 26.69 EUR | -15.05% |
|
| Current month | -27.08% | ||
| 1 month | -50.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 26.69 | -15.05% |
| 24-05-20 | 31.42 | -6.99% |
| 24-05-17 | 33.78 | +4.39% |
| 24-05-16 | 32.36 | -0.74% |
| 24-05-15 | 32.6 | -14.97% |
Real-time Euronext Paris
Last update May 21, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 4M93S | |
| ISIN | DE000SU9DH20 |
| Date issued | 2024-02-15 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 55.87 € |
|---|---|
| Lowest since issue | 24.87 € |
| Spread | 0.27 € |
| Spread % | 1.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- 4M93S Certificat
